Clinical trial · no report yet · Phase 2
NCT04434040
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
- NCT04434040 ↗
- Recruiting
- Dana-Farber Cancer Institute
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 3 | |
| X threads | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Single Arm Phase 2 Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Breast Cancer; Triple Negative Breast Cancer; Residual Cancer; Circulating Tumor DNA
- Interventions
- Atezolizumab; Sacituzumab govitecan
- Arms
- Atezolizumab and Sacituzumab govitecan · Experimental
- Enrollment
- 40 (estimated)
- Primary outcomes
- Rate of undetectable circulating tumor cfDNA- 6 Cycles
- Sponsor
- Dana-Farber Cancer Institute with Genentech, Inc., Stand Up To Cancer
- Start
- Jul 2, 2020
- Primary completion
- Dec 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04434040 · updated May 4, 2026